Minimally Invasive Splenectomy for Oncological Diseases of the Spleen
Laparoscopic splenectomy (LS) has become the gold standard procedure for the treatment of benign hematological disorders not associated with splenomegaly, such as idiopathic thrombocytopenic purpura (ITP) [1, 2]. The great advances in minimally invasive surgery (MIS) that have been made over the last two decades did also benefit patients suffering from hematological malignant diseases However, this patients usually develop splenomegaly and the endoscopic manipulation of bulky organs is technically more challenging, and retrieval of the specimen may prove difficult. Splenomegaly was initially considered a contraindication for LS, thus, many malignant hematological diseases which are associated with an enlarged spleen were traditionally reserved for open splenectomy (OS) with its associated increased morbidity. Improvements and refinement of LS techniques have resulted in the ability to remove an enlarged spleen using the laparoscopic approach and preserving all the advantages of the MIS [3–5].
KeywordsLaparoscopy Spleen Cancer Splenomegaly
Hand assisted splenectomy (HALS) (MPG 23982 kb)
Hand assisted splenectomy (HALS). Targarona (MP4 374061 kb)
- 11.NCCN. Clinical practice guidelines in oncology™. Non-Hodgkin’s Lymphoma. V.3.2007. www.nccn.org.
- 21.Rodriguez-Otero Luppi C, Targarona Soler EM, Balague Ponz C, et al. Clinical, anatomical, and pathological grading score to predict technical difficulty in laparoscopic splenectomy for non-traumatic diseases. World J Surg. 2017,41:439–448, doi: 10.1007/s00268–016-3683-y.